Welcome to our dedicated page for Dss news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on Dss stock.
DSS Inc (NYSE American: DSS) delivers cutting-edge security solutions and diversified business innovations across five global sectors. This news hub provides investors and industry professionals with authoritative updates on the company's anti-counterfeit technologies, biotechnology advancements, and financial strategies.
Access real-time announcements covering DSS's intellectual property developments, strategic partnerships, and operational milestones. Our curated collection includes earnings reports, product launch details, and leadership updates from the brand protection pioneer.
Key focus areas include patent acquisitions in authentication systems, biotech research breakthroughs, and commercial lending initiatives. Stay informed about DSS's global expansion efforts and cross-industry collaborations through verified press releases.
Bookmark this page for direct access to DSS's official communications, ensuring you never miss critical updates affecting market positioning across their product packaging, investment management, and direct marketing divisions.
Impact Biomedical, a subsidiary of Document Security Systems (DSS), announced major updates on its research projects aimed at addressing global challenges in biotechnology. Key collaborations and advancements were highlighted, including the Procombin study to improve antibiotics and the CRST-1 molecule, which shows promising results in cancer treatment. The company is also exploring global licensing for several products, such as Equivir and Linebacker. This strategic focus on innovation positions Impact Biomedical as a potential leader in the biotech industry.
Document Security Systems (DSS) announced the launch of Liquid Value Asset Management Limited (LVAM) through its subsidiary, DSS Financial Management Inc. This fund management company, based in Hong Kong, will focus on algorithmic trading across various financial instruments. The team, including former Societe Generale and Citadel professionals, boasts a track record of 20% annual returns and a Sharpe ratio above 2.0. CEO Frank D. Heuszel expressed confidence in rapidly growing LVAM's trading assets to over $1 billion.
Document Security Systems (DSS) has announced a significant expansion in its investment in American Medical REIT (AMRE) through a $2.6 million share purchase, increasing its ownership from 52% to 99%. This investment will fund the acquisition of Ivy Brook Medical Center in Shelton, Connecticut, a prestigious 40,000 square-foot facility. CEO Frank Heuszel highlighted the resilience of the health services real estate sector, citing nearly 100% rent collection rates compared to pre-COVID levels. DSS aims to leverage its expertise to enhance AMRE's portfolio.
Aegis Capital Corp. acted as the Sole Bookrunner for a $50 million public offering of common stock for Document Security Systems, Inc. (DSS), including the exercise of the over-allotment option. This offering is aimed at securing capital for the company's diverse operations, which encompass brand protection technology, blockchain security, and direct marketing, among others. DSS's model includes strategically spinning out subsidiaries through IPOs, potentially enhancing shareholder value.
Document Security Systems, Inc. (NYSE American: DSS) announced the closing of a public offering generating $50.025 million in gross proceeds. The offering consisted of 29 million shares at $1.50 per share, with an additional 4.35 million shares sold via the underwriters' over-allotment option. These funds will support growth in new business lines, acquisitions, and general corporate needs. The offering was executed under a shelf registration statement effective as of June 7, 2021.
Document Security Systems (DSS) announced that its subsidiary, Impact BioMedical, received a patent from the USPTO for its 3FDB, a revolutionary mosquito repellent technology. This formulation enhances existing repellents like DEET by targeting multiple mosquito receptors to provide superior efficacy. The team discovered its active ingredients in the ghost orchid, which naturally repels mosquitoes. With the mosquito repellent market projected to reach $1.2 billion by 2025, DSS aims to leverage this innovation to save lives and address global health challenges related to mosquito-borne diseases.
Document Security Systems, Inc. (DSS) has priced a public offering of 29 million shares at $1.50 per share, aiming for gross proceeds of approximately $43.5 million. The funds will support the company's expansion into new business lines and cover working capital needs. Additionally, underwriters have an option to purchase up to 15% more shares, potentially raising total proceeds to $50 million. The offering is filed under a shelf registration statement effective June 7, 2021.
DSS acquires 24.9% of Sentinel Brokers Company, Inc. as part of its strategic expansion in the financial services sector. The agreement includes an option to buy an additional 50.1%, aimed at enhancing the ecosystem around DSS Securities. Established in 1996, Sentinel, a FINRA-registered broker-dealer, specializes in institutional trading of bonds and preferred stocks. DSS aims to leverage this acquisition to accelerate its digital securities business and capitalize on growth opportunities in the industry.
Document Security Systems (DSS) has launched a new subsidiary, DSS PureAir, focusing on air purification technology. Recent studies from the University of Florida show that products from Puradigm, a company DSS invested in, can effectively neutralize SARS-CoV-2 on surfaces, with a 97.7% decrease in viral infectivity after four hours. The air purifier market, valued at $10.7 billion in 2020, is projected to grow by 10% annually until 2028. DSS PureAir aims to capitalize on this growth with advanced purification solutions.
Document Security Systems (DSS) announced that Proof Authentication Corporation has acquired 100% of DSS Digital, Inc., enhancing shareholder value by focusing on higher-return opportunities. The agreement allows DSS to license its anti-counterfeit technology to key customers while investing in growth areas like healthcare and renewable energy. The deal includes upfront cash and potential earn-out payments based on revenue targets. CEO Frank D. Heuszel highlighted the shift towards innovative solutions, indicating a strategic move to revitalize DSS's operations and drive market value.